Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A. McArthur, Axel Hauschild, John B.A.G. Haanen et al.|The Lancet Oncology|2014Cited by 978
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyPaul B. Chapman, Grant A. McArthur, Caroline Robert et al.|Annals of Oncology|2017Cited by 258